Orexigen Therapeutics Announces Departure of CFO

Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, has announced the upcoming resignation of Graham Cooper, senior vice president (SVP), finance, chief financial officer (CFO) and treasurer. Cooper, who has been with Orexigen for over four years, has decided to leave for personal reasons. He will remain in his current role at Orexigen until the reporting of the company’s year-end results and the filing of its annual report on Form 10-K with the SEC for the year ended 31 December 2010.

The company will name Jay Hagan, SVP, corporate development and strategy, as acting-CFO and transition the financial operation responsibilities to him. Hagan joined the company in May 2009 after 10 years at Amgen. He was instrumental in helping Orexigen secure the partnership with Takeda Pharmaceuticals North America for Contrave (naltrexone Sustained Release (SR)/bupropion SR). Since joining the company to lead corporate development in 2009, Hagan has taken on increased responsibility, leading the corporate communications and technical operations functions at Orexigen.

Steve Moglia, senior director of financial reporting and controller, and Judy Fox, assistant controller, will continue to play key leadership roles in Orexigen’s finance department. Moglia joined Orexigen in 2008 and is responsible for managing all financial reporting, Sarbanes-Oxley compliance, stock administration and tax compliance activities. Prior to joining Orexigen, he served as the director of SEC reporting and compliance at Biosite. Moglia is a certified public accountant (CPA) (inactive) in California.

Fox joined Orexigen in 2007 and is responsible for accounting, financial management, 401(k) and other accounting related administrative functions. Prior to joining Orexigen, she served as assistant controller at Diversa Corporation. Fox received her MBA from California State University, San Marcos.


Related reading